No Data
TONG REN TANG (01666.HK) 2024 annual performance: revenue increased by 7.18% to 7.26 billion yuan, steadily advancing the Global Strategy for major products.
Gelonghui, March 28 - TONG REN TANG (01666.HK) announced its annual results. In 2024, the group will continue to deeply implement the "14th Five-Year Plan", maintaining its focus on the "TONG REN TANG Service Year" main line, and unflinchingly executing the "Big Variety" core Global Strategy. For the year ending December 31, 2024, the group's revenue was 7.26 billion RMB, an increase of 7.18% compared to the same period last year; the Net income reached 0.887 billion RMB, with a Net income attributable to owners of the company at 0.522 billion RMB, and the EPS was 0.41 RMB, with a dividend per share of 0 RMB.
TONG REN TANG: Launched the "Organic Version" of the An Gong Niu Huang Wan.
To meet the market and Consumer demand for emergency medications for cardiovascular diseases, Peking TONG REN TANG Technology Development Co., Ltd. (hereinafter referred to as "TONG REN TANG") is rooted in tradition, fully leveraging the advantages of authentic medicinal materials and scientific research innovations, and has launched the An Gong Niu Huang Wan (Organic Cultivated Version). Currently, distribution has been completed in TONG REN TANG affiliated pharmacies, and work continues to implement distribution in key cooperative chains outside the system. An Gong Niu Huang Wan is a well-known product of TONG REN TANG, with the functions and indications of clearing heat and detoxifying, settling fright and opening the orifices. It is used for febrile diseases, evil entering the pericardium, high fever and convulsions, and confusion with delirium; it is also used for coma from stroke, encephalitis, meningitis, toxic encephalopathy, cerebral hemorrhage, and septicemia as mentioned above.
TONG REN TANG (01666) released its annual performance, with a net income of 0.522 billion yuan, a year-on-year decrease of 11.59%.
TONG REN TANG (01666) announced its annual performance for the year ending December 31, 2024, with the group's revenue being 72...
Policy dividends combined with a stable raw material market have started a new cycle of value for TONG REN TANG (01666.HK).
The 2025 government work report once again clarifies the core direction for the high-quality development of the Medical health industry, with policies continuously releasing Bullish signals for the inheritance and innovation of Traditional Chinese Medicine, deepening the hierarchical diagnosis and treatment system, and cultivating the Silver economy. Recently, the Traditional Chinese Medicine industry welcomed another Bullish policy, as the General Office of the State Council issued the "Opinions on Improving the Quality of Traditional Chinese Medicine and Promoting the High-Quality Development of the Traditional Chinese Medicine Industry," which proposes 21 key items in 8 areas including enhancing the development level of Traditional Chinese Medicine materials, accelerating the transformation and upgrading of the Traditional Chinese Medicine industry, and strengthening the quality supervision of Traditional Chinese Medicine.
TONGRENTANGCM (03613.HK) intends to confiscate unclaimed dividends.
Globefinance reported on March 28 that TONGRENTANGCM (03613.HK) announced that the final dividend of HKD 0.19 per ordinary share for the year ended December 31, 2017, which was declared on March 12, 2018, will be forfeited and returned to the company if it has not been claimed by April 30, 2025 (Wednesday).
TONGRENTANGCM (03613): Feng Li has been appointed as a member of the nomination committee.
TONGRENTANGCM (03613) issued an announcement that starting from March 28, 2025, the company's non-executive director Ms. Feng Li...
